Hyman Steven E
Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Neuropsychopharmacology. 2014 Jan;39(1):220-9. doi: 10.1038/npp.2013.181.
Despite high prevalence and enormous unmet medical need, the pharmaceutical industry has recently de-emphasized neuropsychiatric disorders as 'too difficult' a challenge to warrant major investment. Here I describe major obstacles to drug discovery and development including a lack of new molecular targets, shortcomings of current animal models, and the lack of biomarkers for clinical trials. My major focus, however, is on new technologies and scientific approaches to neuropsychiatric disorders that give promise for revitalizing therapeutics and may thus answer industry's concerns.
尽管神经精神疾病患病率高且存在巨大的未满足医疗需求，但制药行业最近已不再强调该领域，认为其是“过于困难”的挑战，不值得进行重大投资。在此，我描述了药物研发的主要障碍，包括缺乏新的分子靶点、当前动物模型的缺陷以及临床试验缺乏生物标志物。然而，我的主要关注点是针对神经精神疾病的新技术和科学方法，这些技术有望振兴治疗方法，从而回应行业的担忧。
